Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 5/2018

01-05-2018 | Pictorial essay

MRI for hepatocellular carcinoma: a primer for magnetic resonance imaging interpretation

Authors: Tina Sanghvi, James Boyum, Ben Spilseth, Robben Schat, Heather Estby, Andrew Taylor

Published in: Abdominal Radiology | Issue 5/2018

Login to get access

Abstract

Hepatocellular carcinoma is among the most prevalent solid organ cancers, and, unlike many cancers, may be diagnosed non-invasively by imaging criteria [1] with the preferred modality recently shifting from multiphasic computed tomography (MDCT) to magnetic resonance imaging (MRI). The purpose of this article is to help facilitate radiologists and radiology trainees in the transition to MRI by providing a step-wise approach to exam interpretation to improve the MRI detection of HCC. A methodical, consistent approach to navigating a HCC screening MRI exam, in conjunction with the LI-RADS framework for characterization, should lead to improved HCC detection and diagnosis.
Literature
1.
Llovet JM, Ducreux M, Lencioni R, et al. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. Eur J Cancer 48(5):599–641. doi:10.​1016/​j.​ejca.​2011.​12.​021 CrossRef
2.
3.
Lee YJ, Lee JM, Lee JS, et al. (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-A systematic review and meta-analysis. Radiology 275:97–109CrossRefPubMed
4.
Sirlin CB, Hussain HK, Jonas E, et al. (2014) Consensus report from the 6th International forum for liver MRI using gadoxetic acid. J Magn Reson Imaging 40(3):516–529CrossRefPubMed
5.
Rostambeigi N, Taylor AJ, Golzarian J, et al. (2016) Effect of MRI versus MDCT on Milan criteria scores and liver transplantation eligibility. AJR 206:726–733CrossRefPubMed
6.
Llovet JM, Bustamante J, Castells A, et al. (1999) Natural history of untreated nonsurgical hepatocellular carcinoma (Rationale for the design and evaluation of therapeutic trials). Hepatology 29:62–67CrossRefPubMed
7.
Danatoa J, Fracncab M, Candeláriaa I, Caseiro-Alvesa P (2017) Liver MRI: from basic protocol to advanced techniques. Eur J Radiol 93:30–39CrossRef
8.
9.
Ikram , et al. (2017) Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. Abdom Radiol 42:870–876CrossRef
10.
Hanna RF, Diego AA, Kased N, et al. (2008) Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. RadioGraphics 28:747–769CrossRefPubMed
11.
Rosenkrantz AB, Lee L, Matza BW, Kim S (2012) Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol 67:105–111CrossRef
12.
Foley WD, Mallisee TA, Honhenwalter MD, et al. (2000) Multiphase hepatic CT with a multirow detector CT scanner. AJR 175:679–685CrossRefPubMed
13.
Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of Liver Imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRefPubMed
14.
Goncalves Neto JA, Altun E, Vaidean G, et al. (2009) Early contrast enhancement of the liver: exact description of subphases using MRI. Magn Reson Imaging 27(6):792–800CrossRefPubMed
15.
Choi J-Y, Lee J-M, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRefPubMedPubMedCentral
16.
Huang B, Wu L, Lu X-Y, et al. (2016) Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging. Radiology 281:150–157CrossRefPubMed
17.
Parikh T, Drew SJ, Lee VS, et al. (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822CrossRefPubMed
18.
19.
Vandecaveye V, De Keyzer F, Verslype C, et al. (2009) Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 19:2456–2466CrossRefPubMed
20.
Yu J-S, Chung J-J, Kim Jh, Kim KW (2007) Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR 188:1009–1016CrossRefPubMed
21.
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2000) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33(2):282–289CrossRefPubMed
22.
International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664CrossRef
23.
Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654CrossRefPubMedPubMedCentral
24.
Prasad SR, Wang H, Humberto R, et al. (2005) Fat-containing lesions of the liver: radiologic- pathologic correlation. RadioGraphics 25:321–331CrossRefPubMed
25.
Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183(3):819–825CrossRefPubMed
26.
Matsui O, Kadoya M, Kameyama T, et al. (1989) Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 173(1):123–126CrossRefPubMed
27.
Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR, imaging of hepatocellular Carcinoma in the cirrhotic liver: challenges and controversies1. Radiology 247:311–330CrossRefPubMed
28.
Davenport MS, Viglianti BL, Al-Hawary MM, et al. (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461CrossRefPubMed
29.
Neri E, Bali MA, Ba-Ssalamah A, et al. (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRefPubMed
30.
Merkle EM, Zech CJ, Bartolozzi C, et al. (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674–682CrossRefPubMed
31.
Bashir MR, Rajan RT, Davenport MS, et al. (2013) Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? JMRI 37:398–406CrossRefPubMed
32.
Danatoa J, Fracncab M, Candeláriaa I, Caseiro-Alvesa P (2017) Liver MRI: from basic protocol to advanced techniques. Eur J Radiol 93:30–39CrossRef
33.
Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44(7):793–798CrossRefPubMed
34.
Suh YJ, Kim MJ, Choi JY, et al. (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR 197(1):W44–W52CrossRefPubMed
35.
Bashir MR (2014) Magnetic resonance contrast agents for liver imaging. Magn Reson Imaging Clin N Am 22:283–293CrossRefPubMed
Metadata
Title
MRI for hepatocellular carcinoma: a primer for magnetic resonance imaging interpretation
Authors
Tina Sanghvi
James Boyum
Ben Spilseth
Robben Schat
Heather Estby
Andrew Taylor
Publication date
01-05-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1280-7

Other articles of this Issue 5/2018

Abdominal Radiology 5/2018 Go to the issue

OriginalPaper

Traumatic abdominal aortic injury: clinical considerations for the diagnostic radiologist

Classics in Abdominal Imaging

Nutmeg liver

OriginalPaper

Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings

Classics in Abdominal Imaging

Phrygian cap

OriginalPaper

Quantitative MRI of fatty liver disease in a large pediatric cohort: correlation between liver fat fraction, stiffness, volume, and patient-specific factors

OriginalPaper

Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits